ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "pulmonary complications"

  • Abstract Number: 2945 • 2015 ACR/ARHP Annual Meeting

    Diffuse Alveolar Hemorrhage in SLE:  Risk Factors, Response to Therapy, and Survival

    Nayef M. Kazzaz1, Patrick S. Coit2, Emily E. Lewis3, W Joseph McCune4, Amr H. Sawalha2 and Jason S. Knight2, 1Rheumatology, University of Michigan, Ann Arbor, MI, 2Division of Rheumatology, University of Michigan, Ann Arbor, MI, 3University of Michigan, Ann Arbor, MI, 4Int Med/ Rheum, University of Michigan, Ann Arbor, MI

    Background/Purpose:  While diffuse alveolar hemorrhage (DAH) is recognized as a life-threatening complication of SLE, little is known about its risk factors and response to therapy. …
  • Abstract Number: 1504 • 2015 ACR/ARHP Annual Meeting

    Increased Risk of Thromboembolism Among Patients with VTE Association with Rheumatoid Arthritis

    Howard Amital1,2 and Arnon-Dov Cohen3, 1Department of Medicine B, Center for Autoimmune Diseases, Sheba Medical Center, Tel-hashomer, Israel, 2Department of Internal Medicine 'D', Sackler Faculty of Medicine, Tel-Aviv University, Kfar-Saba, Israel, 3Chief Physician's Office, Clalit Health Services, Tel Aviv, Israel

    Increased risk of thromboembolism among patients with VTE association with Rheumatoid Arthritis  Background/Purpose: Rheumatoid arthritis (RA), is among most common autoimmune conditions manifested by progressive and…
  • Abstract Number: 1077 • 2015 ACR/ARHP Annual Meeting

    High Levels of CCL-18 Are Associated with Deterioration of Lung Function, Increased Annual Fibrosis Progression Rate and Decreased Survival in Systemic Sclerosis

    Anna-Maria Hoffmann-Vold1,2, Anders Heiervang Tennøe2, Oyvind Midtvedt1, Torhild Garen3, May Brit Lund4, Trond Mogens Aalokken5, Cathrine Brunborg6, Thor Ueland2 and Øyvind Molberg7, 1Rheumatology, Oslo University Hospital, Oslo, Norway, 2Institute of clinical medicine, University of Oslo, Oslo, Norway, 3Rheumatology, Department of Rheumatology, Oslo University Hospital, Oslo, Norway, 4Respiratory Diseases, Oslo University Hospital, Oslo, Norway, 5Radiology, Oslo University Hospital, Oslo, Norway, 6Biostatistics, Epidemiology and Health Economics, Oslo University Hospital, Oslo, Norway, 7Department of Rheumatology, Institute of Clinical Medicine, Oslo University Hospital, Oslo, Norway

    Background/Purpose: Systemic sclerosis (SSc) carries high risk for progressive interstitial lung disease (ILD), but biomarkers for individual risk stratification are largely missing. There is an…
  • Abstract Number: 845 • 2015 ACR/ARHP Annual Meeting

    Modelling of Longitudinal Changes in Lung Function in Patients with Systemic Sclerosis and Their Association with Development of Pulmonary Hypertension

    Svetlana I. Nihtyanova1, Voon H. Ong1 and Christopher P. Denton2, 1Rheumatology, UCL Division of Medicine, London, United Kingdom, 2Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom

    Background/Purpose: The majority of published models for prediction of PH use cross-sectional data, while studies exploring the use of repeated measurements of lung function tests…
  • Abstract Number: 516 • 2014 ACR/ARHP Annual Meeting

    The Safety and Treatment Efficacy of Abatacept in Rheumatoid Arthritis Patients with Pulmonary Complications: From the Tsurumai Biologics Communication Registry (TBCR) Multicenter Study

    Shinya Hirabara1, Toshihisa Kojima2, Nobunori Takahashi2, Yuji Hirano1, Atsushi Kaneko3, Daihei Kida4, Yasuhide Kanayama5 and Naoki Ishiguro2, 1Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan, 2Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, 3Orthopedic Surgery and Rheumatology, Nagoya Medical Center, Nagoya, Japan, 4Orthopedic Surgery and Rheumatology, Nagoya Medical Center, National Hospital Organization, Nagoya, Japan, 5Orthopedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Japan

    Background/Purpose: Roughly 10-30% of rheumatoid arthritis (RA) patients reportedly develop pulmonary complications. These patients are at increased risk of MTX or biologics-induced damage, which often…
  • Abstract Number: 2697 • 2014 ACR/ARHP Annual Meeting

    Gender Disparities in Lung Transplantation in Patients with Systemic Sclerosis-Related Interstitial Lung Disease and Pulmonary Hypertension

    Elizabeth Volkmann1, Daniel E. Furst2, Rajeev Saggar3, Philip J. Clements4, Bryant Torres5, Lynne Yoder1 and Rajan Saggar1, 1Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 2University of California, Los Angeles, CA, 3Cardiothoracic Surgery, University of Arizona College of Medicine, Phoenix, AZ, 4University of California, Los Angeles, Department of Medicine, Los Angeles, CA, 5Health Policy and Management, Rollins School of Public Health, Emory University, Atlanta, GA

    Background/Purpose: Lung transplantation is often the most viable option for patients with severe systemic sclerosis (SSc)-associated interstitial lung disease (ILD) that is unresponsive to pharmacologic…
  • Abstract Number: 1691 • 2014 ACR/ARHP Annual Meeting

    Systemic Sclerosis Patients with Pulmonary Hypertension Have a Lower Change in End Tidal Carbon Dioxide Following Three Minutes of Step Exercise Than Systemic Sclerosis Patients without Pulmonary Hypertension: A Cross-Sectional Study

    Elana J. Bernstein1, Jessica K. Gordon2, Robert F. Spiera2, Wei-Ti Huang3, Evelyn M. Horn4 and Lisa A. Mandl2, 1Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, 2Rheumatology, Hospital for Special Surgery, New York, NY, 3Biostatistics, Hospital for Special Surgery, New York, NY, 4Cardiology, New York Presbyterian Hospital/Weill Cornell Medical College, New York, NY

    Background/Purpose: Pulmonary hypertension (PH) is a leading cause of death in patients with systemic sclerosis (SSc).  Transthoracic echocardiogram and pulmonary function testing are standard noninvasive…
  • Abstract Number: 1678 • 2014 ACR/ARHP Annual Meeting

    Initial Therapy with an Endothelin Receptor Antagonist Is Associated with Worse Outcomes in Patients with Systemic Sclerosis and Pulmonary Arterial Hypertension: Observations from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Cohort

    Matthew R. Lammi1, Lesley Ann Saketkoo2, Stephen C. Mathai3, Robyn T. Domsic4, Christine M. Bojanowski5, Virginia D. Steen6, Daniel E. Furst7 and Pharos Investigators8, 1Section of Pulmonary and Critical Care Medicine, LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, 2LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, 3Medicine, Johns Hopkins University, Baltimore, MD, 4Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, 5Internal Medicine and Pediatrics, LSU Health Sciences Center, New Orleans, LA, 6Department of Rheumatology, Georgetown University Medical Center, Washington, DC, 7University of California, Los Angeles, Department of Medicine, Los Angeles, CA, 8Georgetown University Medical Center, Washington, DC

    Background/Purpose: Pulmonary arterial hypertension (PAH) is a leading cause of mortality in systemic sclerosis (SSc).  Although medications have improved their prognosis, optimal therapy remains undefined.…
  • Abstract Number: 734 • 2014 ACR/ARHP Annual Meeting

    Lower Socioeconomic Status, Male Gender and Diffuse Scleroderma Are Associated with Worse Survival in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Cohort

    Jessica K. Gordon1, Wei Zhang2, Lorinda Chung3, Yan Ma4, Virginia D. Steen5 and PHAROS Investigators, 1Rheumatology, Hospital for Special Surgery, New York, NY, 2Healthcare Research Institute, Hospital for Special Surgery, New York, NY, 3Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, 4Research - Epidemiology and Biostatistics, Hospital for Special Surgery, New York, NY, 5Department of Rheumatology, Georgetown University Medical Center, Washington, DC

    Background/Purpose Lower socioeconomic status (SES) and male gender have been associated with worse survival in idiopathic pulmonary arterial hypertension (PAH).  Pulmonary Hypertension Assessment and Recognition…
  • Abstract Number: 2588 • 2013 ACR/ARHP Annual Meeting

    Pulmonary Hypertension In Patients With Anti-U1-RNP Antibodies

    Vincent Sobanski1, Bernadette Lynch2, Benjamin E. Schreiber3, Svetlana I. Nihtyanova4, Jennifer Harvey5, Clive Handler6, Christopher P. Denton7 and John G. Coghlan8, 1Department of Rheumatology, Royal Free Hospital, London, United Kingdom, 2Department of Rheumatology, The Royal Free Hospital, London, United Kingdom, 3Royal Free Hospital NHS Foundation Trust, National Pulmonary Hypertension Service, London, United Kingdom, 4Department of Rheumatology, Royal Free and University College Medical School, London, United Kingdom, 5Clinical Immunology, Royal Free Hospital, London, United Kingdom, 6Department of Pulmonary Hypertension, The Royal Free Hospital, London, United Kingdom, 7Centre for Rheumatology, Royal Free and University College Medical School, London, United Kingdom, 8National Pulmonary Hypertension Service, The Royal Free Hospital NHS Foundation Trust, London, United Kingdom

    Background/Purpose: Pulmonary hypertension (PH) is a leading cause of morbidity and mortality in patients with connective tissue diseases (CTD). Patients with anti-U1-RNP antibodies belong to…
  • Abstract Number: 2591 • 2013 ACR/ARHP Annual Meeting

    Scleroderma Renal Crisis and Pulmonary Arterial Hypertension Are Very Rare In The Same Patient

    Bernadette Lynch1, Vincent Sobanski1,2, Clive Handler3, Benjamin E. Schreiber4, John G. Coghlan5, Voon H. Ong6, Aine Burns7 and Christopher P. Denton8, 1Department of Rheumatology, The Royal Free Hospital, London, United Kingdom, 2Service de médecine interne, Centre National de Référence de la Sclérodermie Systémique, Hôpital Claude Huriez, CHRU Lille, Lille, France, 3Department of Pulmonary Hypertension, The Royal Free Hospital, London, United Kingdom, 4Royal Free Hospital NHS Foundation Trust, National Pulmonary Hypertension Service, London, United Kingdom, 5National Pulmonary Hypertension Service, The Royal Free Hospital NHS Foundation Trust, London, United Kingdom, 6Department of Rheumatology, The Royal Free and University College Medical School, London, United Kingdom, 7Department of Nephrology, The Royal Free Hospital, London, United Kingdom, 8Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School Royal Free Campus, London, United Kingdom

    Background/Purpose: Systemic Sclerosis (SSc) is associated with occlusive vasculopathy resulting in digital ischaemia, telangiectasia, scleroderma renal crisis (SRC) and pulmonary arterial hypertension (PAH). SRC and…
  • Abstract Number: 1745 • 2013 ACR/ARHP Annual Meeting

    Prediction Of Pulmonary Complications In Systemic Sclerosis – Model Development and Validation

    Svetlana I. Nihtyanova1, Benjamin E. Schreiber2, Voon H. Ong3, John G. Coghlan4, Athol U. Wells5 and Christopher P. Denton6, 1Department of Rheumatology, Royal Free and University College Medical School, London, United Kingdom, 2Royal Free Hospital NHS Foundation Trust, National Pulmonary Hypertension Service, London, United Kingdom, 3Department of Rheumatology, The Royal Free and University College Medical School, London, United Kingdom, 4National Pulmonary Hypertension Service, The Royal Free Hospital NHS Foundation Trust, London, United Kingdom, 5Royal Brompton and Harefield NHS Foundation Trust, Department of Radiology, London, United Kingdom, 6Centre for Rheumatology, Royal Free and University College Medical School, London, United Kingdom

    Background/Purpose:  Pulmonary complications contribute substantially to systemic sclerosis (SSc) associated morbidity and are the most frequent disease-related cause of death. We explore predictors of clinically…
  • Abstract Number: 1746 • 2013 ACR/ARHP Annual Meeting

    Pericardial Effusions Are Not a Poor Prognostic Factor In Systemic Sclerosis Patients With Pulmonary Hypertension

    Elana J. Bernstein1, Jessica K. Gordon2, Wei-Ti Huang3 and Virginia D. Steen4, 1Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, 2Rheumatology, Hospital for Special Surgery, New York, NY, 3Biostatistics, Hospital for Special Surgery, New York, NY, 4Department of Rheumatology, Georgetown University Medical Center, Washington, DC

    Background/Purpose: Pulmonary hypertension (PH) (defined as a mean pulmonary arterial pressure ≥ 25 mmHg on right heart catheterization) is a leading cause of death in…
  • Abstract Number: 217 • 2012 ACR/ARHP Annual Meeting

    Myositis-Associated Usual Interstitial Pneumonia Has Better Survival Than Idiopathic Pulmonary Fibrosis

    Christine McBurney1, Rohit Aggarwal2, Kevin Gibson3, Kathleen Lindell4, Carl Fuhrman5, Diane Koontz6, Frank Schneider7, Naftali Kaminski4 and Chester V. Oddis8, 1Rheumatology, University of Pittsburgh, Pittsburgh, PA, 2Medicine, University of Pittsburgh, Pittsburgh, PA, 3Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, 4University of Pittsburgh Dorothy P. & Richard P. Simmons Center for Lung Disease, Pittsburgh, PA, 5Radiology, Division of Thoracic Imaging, University of Pittsburgh, Pittsburgh, PA, 6Department of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 7Anatomic Pathology Department, Pittsburgh, PA, 8Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Usual interstitial pneumonia associated with idiopathic pulmonary fibrosis (IPF-UIP) has a poor prognosis with a median survival of 3 years. It is unknown whether…
  • Abstract Number: 723 • 2012 ACR/ARHP Annual Meeting

    Renal Dysfunction and Disease Severity in Scleroderma-Associated Pulmonary Arterial Hypertension

    Stephen C. Mathai1, Laura K. Hummers2 and Virginia D. Steen3, 1Medicine, Johns Hopkins University, Baltimore, MD, 2Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 3Department of Rheumatology, Georgetown University Medical Center, Washington, DC

    Background/Purpose: Renal disease is a common complication of scleroderma (SSc).  Isolated reduction in glomerular filtration rate (GFR), a marker of impaired renal function, can occur…
  • « Previous Page
  • 1
  • 2
  • 3
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.